HM9: From barrier to bridge – Practical strategies for successful advanced therapy medicinal product (ATMP) development
By Bruno Speder2025-11-18T09:57:00
Key points:
- The session focused on the challenges faced by developers of advanced therapy medicinal products (ATMPs), who are at the interplay of different regulations, including the regulations on Genetically Modified Organisms (GMO) and the Medical Device Regulation
- Patient engagement is always essential in clinical development, but even more critical in ATMP development
To read more key points and the session summary, login as a member or register for free using the links below.